Drug Trial Radar · NCT06111183
Evaluation of AUP12602-C as New Topical Treatment for DFUs (DIAMEND STUDY)
Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Jul 21, 2023
Primary completion
Nov 28, 2025
Study completion Nov 28, 2025
Sponsor
- Lead sponsor
- Aurealis OyIndustry
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study performed in diabetic foot ulcer (DFU) patients with chronic non-healing, neuro-ischemic wounds to investigate the safety, tolerability and efficacy of AUP1602-C.
Conditions
- Diabetic Foot Ulcer
Interventions
AUP1602-CBiological
AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
PlaceboOther
Placebo is topically applied on chronic wounds and covered by wound dressing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of local and systematic adverse events (AEs)Time frame: 6 weeks
- Incidence of Wound ClosureTime frame: 20 weeks
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
Institut für Diabetesforschung Muenster GmbH
Münster, Germany
Hauärztliche und Diabetologische Praxis
Pirna, Germany
Ospedale San Donato
Arezzo, Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
AOU Pisana - Ospedale S. Chiara
Pisa, Italy
Ospedale S. Jacopo Pistoia, Diabetologia e Diabetic foot unit Aziendale
Pistoia, Italy
Mikomed
Lodz, Poland
Med-Polonia SP. Z O.O.
Poznan, Poland
PODOS Klinika Leczenia Ran Podema sp. z o.o.
Warsaw, Poland
Lecran Centrum Opieki Nad Ranami
Wroclaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.